Effects of Tissue Plasminogen Activator for Acute Ischemic Stroke at One Year

Tissue Plasminogen Activator-Porous Magnetic Microrods for Targeted Thrombolytic Therapy after Ischemic Stroke

Effects of Tissue Plasminogen Activator for Acute Ischemic Stroke at One Year

Tissue-type plasminogen activator - Wikipedia

Thrombus composition and thrombolysis resistance in stroke - Research and Practice in Thrombosis and Haemostasis

Tenecteplase vs. alteplase for acute ischemic stroke: a systematic review, International Journal of Emergency Medicine

tPA Mobilizes Immune Cells That Exacerbate Hemorrhagic Transformation in Stroke

PDF] The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial

Reperfusion therapy in acute ischemic stroke: dawn of a new era?, BMC Neurology

Signaling pathways involved in ischemic stroke: molecular mechanisms and therapeutic interventions

Efficacy and safety of low dose alteplase for intravenous thrombolysis in Asian stroke patients: a meta-analysis

Tissue Plasminogen Activator Market is estimated to be valued at US$ 2,455.4 million in 2022 and is expected to exhibit a CAGR of 5.2% over the forecast period (2020-2027).

The Neurotoxicity of Tissue Plasminogen Activator? - Jaspreet Kaur, Zonghang Zhao, Gary M. Klein, Eng H. Lo, Alastair M. Buchan, 2004